Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)

BACKGROUND: On the basis of the results of two pivotal phase III clinical trials, eribulin mesylate is currently approved in EU for the treatment of advanced breast cancer (aBC) in patients who have previously received an anthracycline and a taxane in either the adjuvant or the metastatic setting, a...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:ESMO Open
المؤلفون الرئيسيون: Orditura, Michele, Gravina, Adriano, Riccardi, Ferdinando, Diana, Anna, Mocerino, Carmela, Leopaldi, Luigi, Fabozzi, Alessio, Giordano, Guido, Nettuno, Raffaele, Incoronato, Pasquale, Barzelloni, Maria Luisa, Caputo, Roberta, Pisano, Agata, Grimaldi, Giuseppe, Genua, Geppino, Montesarchio, Vincenzo, Barbato, Enrico, Iodice, Giovanni, Lieto, Eva, Procaccini, Eugenio, Mabilia, Roberto, Febbraro, Antonio, Laurentiis, Michelino De, Ciardiello, Fortunato
التنسيق: Artigo
اللغة:Inglês
منشور في: BMJ Publishing Group 2017
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519815/
https://ncbi.nlm.nih.gov/pubmed/28761747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000176
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة